Skip to content

Clinical research

Clinical research at SIRIC ILIAD

Clinical research at SIRIC ILIAD is conducted within departments specialized in the development of new cancer treatments, including:

Clinical research bridges patient care and translational research, allowing patients to access the latest therapeutic and diagnostic innovations. The clinical trials conducted by SIRIC ILIAD result from the transfer of research outcomes from laboratories to clinical research.

These clinical trials cover all three programs of SIRIC ILIAD, ranging from tumor eradication and tumor resistance to quality of life and return to work. This involves evaluating anticancer drugs, immunotherapies, radiotherapy, imaging, diagnostics, as well as the impact of cancer on patients’ quality of life.

The CLIP² ILIAD

 

The CLIP² ILIAD, supported by the GCS IréCAN (a consortium comprising CHU of Nantes, ICO, and CHU of Angers), was accredited by the INCa (French National Cancer Institute) for the third consecutive time in May 2024. CLIP² centers (Certified Early-Phase Clinical Trial Centers) are specialized investigator centers conducting early-phase clinical trials (Phase I, Phase II, and Phase I-II) for new drugs. The CLIP² ILIAD received dual accreditation for its work in both adult and pediatric oncology, with the latter being a particularly underserved area in early-phase trials.

Previous CLIP² projects have led to the creation of the largest network of early-phase clinical trials for all types of cancer in adults and children in Western France, enrolling over 500 patients in 2023. We have also established strong partnerships with private pharmaceutical companies and academic teams in France and internationally, providing privileged access to new targeted therapies (such as Bcl-2 inhibitors and CAR-T cells).

The CLIP² ILIAD aims to launch innovative early-phase trials in the fields of radionuclides, tumor resistance, and social and human sciences. New units will also participate in the CLIP² ILIAD, further facilitating access to therapeutic innovations in Western France.